echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Bayer's TRK inhibitor larotrectinib approved in China

    Bayer's TRK inhibitor larotrectinib approved in China

    • Last Update: 2022-05-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Today, the NMPA official website announced that the marketing application for larotrectinib (larotrectinib sulfate capsules) submitted by Bayer has been approved for the treatment of adult and pediatric patients with solid tumors carrying the NTRK fusion gene


    According to public information, larotrectinib is an "unlimited cancer" therapy, and it is the world's first oral TRK inhibitor designed for patients with NTRK gene fusion cancers


    Screenshot source: NMPA official website

    The full name of NTRK is neurotrophic factor receptor tyrosine kinase


    Larotrectinib is a next-generation, highly specific oral TRK inhibitor originally developed jointly by Bayer and Loxo Oncology (acquired by Eli Lilly and Company), which now owns the global development and commercialization of the drug exclusive rights


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.